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Rheumatoid arthritis (RA) is an autoimmune/inflammatory disorder with a complex genetic component. We report
the first major genomewide screen of multiplex families with RA gathered in the United States. The North American
Rheumatoid Arthritis Consortium, using well-defined clinical criteria, has collected 257 families containing 301
affected sibling pairs with RA. A genome screen for allele sharing was performed, using 379 microsatellite markers.
A nonparametric analysis using SIBPAL confirmed linkage of the HLA locus to RA ( ), withP ! .00005 l pHLA
. However, the analysis also revealed a number of non-HLA loci on chromosomes 1 (D1S235), 4 (D4S1647),1.79
12 (D12S373), 16 (D16S403), and 17 (D17S1301), with evidence for linkage at a significance level of .P ! .005
Analysis of X-linked markers using the MLOD method from ASPEX also suggests linkage to the telomeric marker
DXS6807. Stratifying the families into white or seropositive subgroups revealed some additional markers that
showed improvement in significance over the full data set. Several of the regions that showed evidence for nominal
significance ( ) in our data set had previously been implicated in RA (D16S516 and D17S1301) or in otherP ! .05
diseases of an autoimmune nature, including systemic lupus erythematosus (D1S235), inflammatory bowel disease
(D4S1647, D5S1462, and D16S516), multiple sclerosis (D12S1052), and ankylosing spondylitis (D16S516). There-
fore, genes in the HLA complex play a major role in RA susceptibility, but several other regions also contribute
significantly to overall genetic risk.
Introduction
Rheumatoid arthritis (RA [MIM 180300]) is a chronic,
systemic, inflammatory disease with autoimmune fea-
tures, the etiology of which remains unsolved. A genetic
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component to RA susceptibility has long been estab-
lished by data from twin and family studies. A recent
twin analysis estimated the heritability of RA to be
∼60% (MacGregor et al. 2000). As in other complex
autoimmune disorders with relatively low levels of fa-
milial aggregation, the strength of the genetic component
has also been estimated by computing the value of ls,
which is the relative recurrence risk for siblings of RA
probands compared with that for the general population
(Risch 1990a). In part because of difficulties with disease
definition in population studies, the estimates of ls for
RA vary widely, and range from 2 to 17 (Seldin et al.
1999). A consistent association between RA and human
leukocyte antigen (HLA)–linked genes has been ob-
served in many populations (Ollier and Thomson 1992).
Although current evidence points to a role for HLA-
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DRB1 alleles, the exact identity of theHLA susceptibility
genes has not been established with certainty. It has been
suggested that the HLA region genes account for a sub-
stantial fraction of the genetic component, perhaps as
much as 50% (Deighton et al. 1989). Nevertheless, the
balance of the evidence indicates that genes outside the
HLA region also contribute to RA susceptibility.
In this study, we present the results of a genomewide
screen and affected sib-pair analysis performed on 257
multicase RA families. These families were gathered by
the North American Rheumatoid Arthritis Consortium
(NARAC) for the first large multicenter study of RA
multiplex families based in the United States (Gregersen
1998). This study was undertaken specifically to identify
genes outside of the HLA region; given the increasing
evidence for familial aggregation and genetic overlap
among different autoimmune diseases (Becker et al.
1998), we also looked for evidence of commonmapping
results with other large linkage-mapping studies of au-
toimmune diseases.
Subjects and Methods
NARAC Family Collection
Multiplex RA families were recruited nationwide in
the United States through the 12 participating recruit-
ment centers of NARAC. Informed consent was ob-
tained from every subject, including all participating
family members, and the local institutional review
board’s approval was secured at every recruitment site
prior to the start of enrollment. The criteria for entering
a family into the study were as follows: (1) two or more
siblings satisfied the 1987 American College of Rheu-
matology criteria for RA (Arnett et al. 1988), (2) at least
one of the siblings had documented erosions on hand
X-ray, and (3) at least one of the siblings had disease
onset between the ages of 18 and 60 years. The presence
of psoriasis [MIM 177900], inflammatory bowel disease
(IBD [MIM 266600]) or systemic lupus erythematosus
(SLE [MIM 152700]) was an exclusionary criterion in
affected individuals. Radiographs of both hands were
taken for all affected siblings at the time of recruitment
into the study, unless films taken within 2 years were
available. All the radiographs were scored by a single
radiologist (D.F.), who used a preliminary, locally de-
veloped severity score using a scale of 0–5. The following
criteria were used for this scale: 0, no erosion; 1, subtle
erosion; 2, erosion without joint-space loss; 3, erosion
with joint space loss; 4, complete joint-space loss, with-
out marked bone destruction or joint deformity; and 5,
marked bone destruction, with or without joint defor-
mity. All patients were examined by trained NARAC
personnel at time of entry and were scored for joint
swelling, tenderness, alignment, and range of motion,
according to standard published methods (Spiegel et al.
1987).
The recruitment of RA multiplex families by NARAC
is ongoing, and we plan to repeat the analysis described
in this study in independent data sets, to replicate the
potential linkages we describe here. The summary data
for all markers used in this genome screen can be found
through links at the NARAC Web site. In addition, in-
vestigators may obtain access to individual-level geno-
typing data, digitized X-rays, and associated clinical
data, after a brief application process. Limited quantities
of DNA samples from these families are also available,
upon request and approval, from the NARAC DNA re-
pository, as described at the NARAC Web site.
Laboratory Procedures
Blood samples were collected, for DNA and serum,
from the affected siblings and from their parents, if avail-
able. DNA was isolated from the peripheral mononuclear
cells using a salting-out kit from BIO-101. At the De-
partment of Laboratory Medicine at the University of
Washington, rheumatoid factor (RF) was measured in
each affected sibling by latex-enhanced nephelometric as-
say (Behring Diagnostics), which uses human and rabbit
IgG coated on latex beads as antigen. This assay was
calibrated to the World Health Organization’s interna-
tional standard for RF (Anderson et al. 1970). Broad-
level typing for HLA-DRB1 was performed using allele-
specific PCR to determine HLA allelic groups DRB1*01
through DRB1*18 (Olerup and Zetterquist 1998).
A genomewide screen was performed on 257 families
(table 2), using markers, spaced at ∼10-cM intervals,
from the set8A combo list from the Marshfield map.
Markers were added to the set at certain chromosomal
locations, such as the HLA complex. The entire marker
set consisted of 47 panels (379markers), each containing
markers pooled together according to size and fluores-
cent label (6-FAM, HEX, and NED). Reaction condi-
tions were standard for all markers used, as described
in the Marshfield PCR protocol (at the Marshfield Web
site). Each panel of pooled markers was electrophoresed
on a 310 or 3700 DNA Analyzer (Applied Biosystems).
Data Analysis
Semiautomated sizing of alleles was performed using
the GENESCAN program, version 2.1 (Applied Bio-
systems), and individual genotypes were assigned with
the help of the GENOTYPER program, version 2.1 (Ap-
plied Biosystems). To ensure accuracy of the genotypes,
two individuals manually checked each genotype. We
also ensured that this data set did not contain any MZ
twin pairs, by searching the database for siblings with
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Table 1
Structure of Families in the NARAC Collection
PARENTS
AVAILABLE
NUMBER OF FAMILIES
Overall
( )np 257
With Two
Affected Sibs
( )np 231
With Three
Affected Sibs
( )np 24
With Four
Affected Sibs
( )np 2
Both 36 32 4 0
One 92 84 8 0
None 129 115a 12 2
a From one of these 115 families, five unaffected siblings were avail-
able for analysis. Otherwise, information from unaffected siblings was
not used.
Table 2
Clinical and Demographic Features of Affected Individuals
( ) in the NARAC Collectionnp 546
Clinical/Demographic Feature Value
Female 77.4%
White 90.0%
RF-positive 82.5%
HLA-DRB1*04 positive 70.0%
Hand erosions 94.0%
Mean age at disease onset (years) 39.0
Mean JAM score 29.9
Mean disease duration (years) 16.0
identical genotypes. Five such twin pairs were identified,
and their dates of birth confirmed that they were twins.
We also verified the genetic relationships among indi-
viduals by applying the program RELATIVE (Go¨ring
and Ott 1997) to all the marker data. In this manner,
we identified nine half-sibling pairs and two unrelated
pairs that were originally ascertained as full-siblingpairs.
A nonparametric linkage analysis was performed, us-
ing SIBPAL from the S.A.G.E. version 3.1 package for
all autosomal marker data. We included all data from
affected sib pairs to implement one-sided statistical t-
tests of whether the identity-by-descent sharing departs
from expectations when Mendelian inheritance of the
markers is assumed. A further analysis of those chro-
mosomes with regions showing some evidence of linkage
( ) was performed by examination of all markersP ! .005
on the relevant chromosomes using the ASM program
of GENEHUNTER PLUS, under the Kong and Cox ex-
ponential model. We also analyzed the data allowing for
the possible joint impact of HLA-region loci and other
loci by weighting the Kong and Cox test statistics (Cox
et al. 1999) using the family-specific NPL score at the
chromosome 6 marker, D6S273. For markers on the X
chromosome, the MLOD method provided by the SIB-
PHASE subroutine of ASPEX (Holmans 1998) was used.
We computed a test statistic from the MLOD result by
converting it to a x2 statistic which we assumed followed
a 1:1 mixture of x2 deviates having 0 and 1 df, respec-
tively. We also used the SIBIBD subroutine of ASPEX to
calculate the probability ( ) that sib pairs share 0 allelesr0
identical by descent, given marker data for a location.
The relative recurrence risk (lm) attributable to effects
from a locus, m, that is tightly linked to genetic markers
showing evidence for linkage, was calculated as
(Risch 1990b). Because we used a rather sparse0.25/r0
map with a marker interval of ∼10 cM, these estimates
are likely to be attenuated. With a 10-cM marker map,
the maximum distance from the nearest marker to a
disease-causing locus is 5 cM, and the average distance
is 2.5 cM. To correct for a decrease in lm that can be
expected from use of a sparse map, we calculated an
unattenuated relative recurrence risk, lm
′. The formula
for lm
′ is based on formula 24 of Risch (Risch 1990b).
The unattenuated relative recurrence risk is:
1
1 1 lm
l p 1 ,′m 2{ }(1 2v) lm
where v is the recombination fraction, which we have
set to .025. Descriptive statistics for demographic and
clinical parameters were produced using the SAS
package.
Results
RA Families
A total of 257 multicase families, containing 301 sib-
ling pairs, were collected and analyzed for this initial
genome screen. The distribution of affected siblings in
these families is shown in table 1; in 49.8% of families,
at least one parent was available for analysis. In addition
to the affected siblings from whom DNA was obtained
for the genomewide screen, there were other siblings in
these families who did not participate in this study. In-
formation on the number of siblings in each family nev-
ertheless was available, as were clinical details if the
siblings had been diagnosed with RA. We found that
7.7% of siblings (excluding the affected sib pair required
for ascertainment of a family) were affected with RA.
Under the assumption of a 1% prevalence of RA in the
population, this recurrence risk yields a relative recur-
rence risk (ls) of 7.7. It should be noted, however, that
this figure is a minimum estimate of the relative recur-
rence risk, since the estimates of the population preva-
lence vary and may be !1% (Seldin et al. 1999). On the
other hand, the enrollment process for these familiesmay
be biased toward a higher rate of affected siblings. For
example, families with multiple affected relatives may
be more likely to include at least one sib pair willing to
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participate in the study, so that participation bias may
inflate the recurrence-risk estimate.
The clinical features of the RA patients in these fam-
ilies are summarized in table 2. Approximately 82% of
affected individuals had seropositive disease, and 70%
carried at least one HLA-DRB1*04 allele. The mean age
at onset of disease was 39 years, with mean disease du-
ration of 16 years. The relatively long mean disease du-
ration was reflected in clinical measures of cumulative
joint damage. Each affected sibling was evaluated using
a modified JAM score (Spiegel et al. 1987). The mean
JAM score was 29.9 (range 0–112) of a maximum pos-
sible score of 120. As noted in the Subjects andMethods
section, hand radiographs on all affected siblings were
read and scored on a scale of 0–5 by a single collabo-
rating radiologist. Using this method, the patients with
erosions had a mean X-ray erosion score of 3.4.
Genomewide Screen
The results of the nonparametric analysis using SIB-
PAL are shown graphically in figure 1 and are sum-
marized in table 3. Only markers with P values !.05 are
included in table 3. As expected, markers in the HLA
region (D6S265, D6S1629, and D6S273) showed sig-
nificant sharing (0.56; ). A number of otherP ! .00005
regions on chromosomes 1 (D1S235), 4 (D4S1647), 12
(D12S373), 16 (D16S403), and 17 (D17S1301) showed
linkage at a significance level of . On the XP ! .005
chromosome, there was marginally significant evidence
for linkage to GATA52b03, with a P value of .016. In
general, the analysis using the Kong and Cox exponen-
tial model showed evidence of linkage with the same
chromosomal regions as did the analysis using SIBPAL
(fig. 2). However, weighting the Kong and Cox LOD
scores by the NPL test statistic from D6S273 did not
lead to more-significant findings for any previously iden-
tified loci. Interestingly, on chromosome 17, weighting
by D6S273 results eliminated evidence for linkage, pos-
sibly suggesting an inverse relationship in risk conferred
by putative genetic factors on these two chromosomes
(results not shown). Further results of these analyses can
be found at the NARAC Web site.
In addition to analyzing the entire data set for linkage,
we stratified the sibling pairs to examine whether linkage
observed in the entire data set was contributed mainly
by any one of the following subsets: (1) both siblings
had disease onset before age 45 years, (2) the siblings
were white, or (3) both siblings were seropositive for RF
(RF 111 IU/ml). We selected the age of 45 years as a
cut-off for early-onset disease, given that the mean age
at onset for RA among first-degree relatives in multiplex
families has been reported as 46 years (Lynn et al. 1995).
This subgroup, where both affected siblings in a pair
had disease onset before age 45 years, did not make any
disproportionate contribution to the linkage demon-
strated in the entire data set. Among the white families
( ), three markers showed a much higher levelnp 230
of significance than they did among all subjects
(D3S3038, D3S2409, and D17S1308; withinP ! .005
the subgroup). The markers showing stronger evidence
for linkage in the seropositive subgroup ( ) werenp 185
D5S1462 and D12S373 ( within the subgroup).P ! .005
The latter marker exhibited considerable improvement
in significance ( within the subgroup) com-Pp .00004
pared with the full data set ( in the full set).Pp .0031
To evaluate the significance of this finding, we performed
some further analytical studies. We calculated the cor-
relation among tests for each pair of subgroups and
found the average correlations among the subgroup tests
to be 0.6256. Then we found the critical value corre-
sponding to , which is 3.944. Finally, wePp .00004
obtained the nominal significance level corresponding to
a three-dimensional test with this critical value, and the
common correlation among the tests using software
from Dunnett (STATLIB; Dunnett et al. 1989). By set-
theory rules, this nominal significance is three times the
nominal significances of the univariate tests, minus three
times the bivariate tests, plus the trivariate test. The re-
sulting P value is .00007. Overall, we had conducted 33
tests, and we had only tested regions that showed sig-
nificance at the .05 level. For significance using these 33
tests and Sidak’s (1967) correction, , wenPp 1 (1 p)
required a P value !.0000759; that is, 0.0025p 1
. Technically, the subgroup finding for33(1 0.000759)
D12S373 is just significant, at the .05 level, after cor-
rection for multiple tests and for the fact that we required
a significant result before further study. However, fol-
low-up studies are needed to confirm this finding, both
to assure a biologically significant finding and because
significance tests are not very reliable in evaluation of
extremely small P values.
Discussion
We report here the first major genomewide screen on
multiplex families with RA that were gathered in North
America. We used 379 markers at intervals of ∼10 cM
in 257 families with erosive RA. One important feature
of the families recruited by NARAC is that all affected
siblings were examined by trained NARAC personnel
using a set of well-defined protocols, thereby mitigating
uncertainty and potential lack of uniformity in clinical
data collection. Moreover, erosion on the hand X-rays
of at least one of the affected siblings in a family was a
criterion for entry into the study; this was done in order
to enhance confidence in the diagnosis of RA, as well
as to provide a measure of disease severity. Overall, 82%
of patients were seropositive for RF, and 70% carried
at least one HLA-DRB1*04 allele. Our patients also
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Table 3
Chromosomal Regions Giving P Values !.05 When SIBPAL 3.1 Is
Used
Locus
No. of
Sib Pairs
Mean
Sharing P
Distancea
(cM)
Chromosome 1:
D1S1631 237 .5426 .0141 137
D1S235 291 .5465 .0048 269
Chromosome 3:
D3S3038 279 .5367 .0139 48
D3S1768 289 .5312 .0283 66
D3S2409 296 .5271 .0491 77
D3S4523 294 .5305 .0288 148
D3S1311 192 .5361 .0408 241
Chromosome 4:
D4S1647 295 .5622 .0001 101
Chromosome 5:
D5S2848 291 .5259 .043 42
D5S1457 290 .5395 .0066 63
D5S1501 253 .5277 .0411 92
D5S1462 286 .5378 .0079 113
Chromosome 6:
D6S1959 267 .5336 .0135 29
D6S265 298 .574 .0000024 34b
D6S1629 299 .5604 .0000297 36b
D6S273 297 .5706 .000003 37b
D6S291 302 .5464 .0013 37b
D6S2439 284 .5472 .0043 40
D6S2427 291 .5315 .031 49
D6S1021 291 .5346 .0075 111
Chromosome 8:
D8S277 293 .536 .0088 4
D8S1110 289 .5357 .0187 70
D8S373 285 .539 .0084 170
Chromosome 9:
ATA59H06 252 .5368 .0244 137
Chromosome 10:
D10S2327 267 .5276 .0462 100
D10S2470 286 .5276 .0476 113
Chromosome 11:
D11S1998 263 .5271 .0258 110
Chromosome 12:
D12S373 296 .5394 .0031 26
D12S398 297 .5393 .0051 57
D12S1052 288 .532 .0227 74
Chromosome 14:
D14S1280 280 .5298 .0174 11
D14S587 267 .5305 .0373 46
Chromosome 16:
D16S403 287 .5473 .0042 33
D16S2624 294 .5278 .0339 76
D16S516 300 .53 .0316 92
Chromosome 17:
D17S1308 287 .529 .0137 0
D17S1298 285 .5348 .0053 12
D17S2180 289 .5363 .0054 73
D17S1301 293 .5431 .0017 120
Chromosome 18:
D18S858 295 .5266 .0433 79
NOTE.—The means test was applied to the affected sib pairs to
evaluate the one-sided hypothesis that identity-by-descent sharing ex-
ceeds the Mendelian expectation of 50%.
a Distances are from the Marshfield map, except where indicated.
b Distance from the Ge´ne´thon map.
have a relatively young mean age at onset, 39 years,
possibly due in part to the requirement that at least one
of the affected siblings had disease onset between the
ages of 18 and 60 years. Thus, overall, the NARAC
collection of RA families contains affected siblings with
relatively early onset and moderately severe erosive
disease.
In order to confirm that nonparametric sib-pair anal-
ysis in our study population would allow us to detect
linkage, we analyzed a few markers from the HLA re-
gion, since this region has previously been linked to RA.
The results for the HLA markers confirmed this linkage
with RA ( ); as shown in table 3, markersP ! .00005
D6S265 and D6S273 achieved significant linkage at the
level suggested by Lander and Kruglyak (P ! 2.2#
) (Lander and Kruglyak 1995). The relative con-510
tribution of HLA (lHLA) to the overall sibling recurrence
risk for RA (ls) was found to be 1.79 in this data set.
This figure for lHLA agrees with that found in the RA
families recruited by the European Consortium for
Rheumatoid Arthritis Families (ECRAF) (Corne´lis et al.
1998).
Using the entire data set, we also calculated the
marker-specific relative recurrence risks for the non-
HLA region loci that showed evidence for linkage
( ), and these were as follows: ,P ! .005 l p 1.14D1S235
, , , andl p 1.32 l p 1.25 l p 1.32D12S373 D16S403 D17S1301
. After correction for attenuation, thel p 1.32D4S1647
relative recurrence risks were ,l p 1.16D1S235
, , , andl p 1.37 l p 1.28 l p 1.37D12S373 D16S403 D17S1301
. Because we used dense markers in thel p 1.37D4S1647
HLA region, we used a value of 1.79 for lHLA for further
calculations using either attenuated or unattenuated re-
currence risks. Risch (1990b) suggested that if multiple
loci interact multiplicatively to affect disease risk, the
sibling relative recurrence risk is determined by the
product of the marker-specific relative recurrence risks.
The manner in which different loci interact to increase
disease risk for RA is unknown; however, the relative
rarity of extended families with RA suggests that a mul-
tiplicative interaction is more consistent with the disease
process than is an additive interaction. The products of
the attenuated and unattenuated relative recurrence
risks for all loci are 5.87 and 6.83, respectively. These
relative recurrence risks are similar to the observed sib-
ling recurrence risk of 7.7 in these families. Although
the HLA region has the largest single impact on the
relative recurrence risk, the joint effects of non-HLA
region genes appear to be greater than those of the HLA
region alone.
Lander and Kruglyak have suggested that significance
in such genomewide screens should be at the level of
for significant linkage. This criterion5P ! 2.2# 10
corresponds to a 5% genomewide significance for a
dense map and completely informative markers (Lander
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and Kruglyak 1995), which are conditions not met by
our study. Overall, excluding the 80-cM region flanking
the HLA complex, we conducted 350 tests using either
SIBPAL or MLOD to examine whether the mean pro-
portion of alleles shared identical by descent in affected
siblings differed from 0.5. We identified 33 tests that
were significant at the .05 nominal level. If we conser-
vatively assume that each test is independent, we would
expect to find ∼18 linkages to be significant at the .05
level, and so we identified more putative linkages than
expected if all linkages were false-positive findings. If
we conservatively assume independence of all tests and
then apply the Sidak (1967) correction for multiple
tests, , at the genomewide significancenPp 1 (1 p)
levels of 5% and 10%, the critical values that we require
are and . By these criteria, mark-4 41.5# 10 3.0# 10
ers in the HLA region and D4S1647 are significant,
whereas D17S1301 reaches a suggestive level of signif-
icance. To assess how correlated tests were with the
nearby markers, we regressed the test statistics from
each marker on the test statistics for the two adjacent
markers to either site of a marker. The result of this
analysis showed that ∼15% of the variability among
tests can be explained by the tests from the four flanking
markers for any particular marker. Because the results
from multiple test adjustments are not markedly af-
fected by low levels of correlation among the tests
(Brown and Russell 1996), application of a Bonferroni
correction is likely to yield a reasonably conservative
adjustment for multiple testing in our study. In a prior
simulation (Zhao et al. 1999), it was found that the
significance corresponding to the LOD score of 3.6 sug-
gested by Lander and Kruglyak was too conservative,
especially when a sparse map and many meioses were
available for study. In reporting potential linkages, we
have used a nonstringent cut-off of , to not missP ! .05
signals from genes that are contributing only a modest
effect. This was done to enable us to target potential
linkages (Thomson 1994; Lander and Kruglyak 1995)
that we will later confirm in independent data sets with
even larger sample sizes. Using this nonstringent P
value, we observed linkage on 14 different chromo-
somes, as summarized in table 3.
A stratification of the family data suggested that the
white and seropositive subgroups may make dispropor-
tionate contributions to allele sharing at some loci.
Among the white families, twomarkers on chromosomes
3 (D3S3038 and D3S2409) and one on chromosome 17
(D17S1308) showed an improved level of significance,
compared with the entire data set. The families recruited
by NARAC are ethnically heterogeneous, although 90%
of the families used in this screen were white. The re-
maining subgroups were primarily Hispanic (5%), black
(3.5%), Asian (0.8%), and American Indian (0.8%). The
results in the white subgroup point to the possibility that
theremay be differences in RA-susceptibility loci between
different ethnic groups. Indeed, this has been suggested
by differences in patterns and strengths of HLA associ-
ations in different ethnic groups (Ollier and Thomson
1992). For example, black and Hispanic populations
with RA do not exhibit a strong association with the
HLA shared epitope (McDaniel et al. 1995; Teller et al.
1996). Thus, it is reasonable to assume that a degree of
genetic heterogeneity is likely to exist at non-HLA sus-
ceptibility loci as well.
The results for the subgroup seropositive for RF (61%
of affected sibling pairs) were the most striking. Marker
D12S373 showed evidence for suggestive linkage at a
level comparable to that of the HLA locus (P !
) in this subgroup. Given the evidence for the.00005
involvement of the tumor necrosis factor (TNF) path-
ways in the pathogenesis of RA, it is notable that this
marker lies within 10 cM of the tumor necrosis factor
receptor 1 (TNFR1) locus.
The linkage found at 16q24.1 in our data set has also
been reported by ECRAF (Corne´lis et al. 1998). That
study is the only other large genomewide screen for RA-
susceptibility genes that has been published. In addition,
a recent meeting report on a candidate-region analysis
of 152 RA sibling pairs indicates that a chromosomal
region (17q22) containing marker D17S1301 also
shows evidence of linkage to RA in families from the
United Kingdom (Barton et al. 2000). It is of interest
that this region is among the strongest linkages revealed
by the Kong and Cox exponential model (fig. 2). We
failed to replicate earlier reports from a Japanese ge-
nome screen showing linkage between markers on 1p36
and RA (Shiozawa et al. 1998). We also did not find
significant evidence for linkage to the region of 3q13
identified by ECRAF (Corne´lis et al. 1998).
RA is often grouped with a family of diseases clas-
sified as “autoimmune” that may share a common
pathogenesis, which implies that a common group of
genes may underlie autoimmunity (Becker et al. 1998).
Therefore, we compared the markers that showed nom-
inal significance in the present study with those reported
as showing linkage to other autoimmune diseases. Five
of the non-HLA chromosomal regions we report in this
study have been implicated in at least one other auto-
immune disease. The region of marker D1S235 (Pp
) in the 1q43-44 region of chromosome 1 was first.0048
implicated in susceptibility to SLE by a candidate-region
approach (Tsao et al. 1997). This region has been linked
to SLE in three independent genome screens (Tsao et al.
1997; Gaffney et al. 1998; Moser et al. 1998). Marker
D4S1647 on chromosome 4q, which demonstrated the
most significant linkage with RA (outside the HLA re-
gion) in our data set ( ), and marker D5S1462Pp .0001
( ) have shown evidence for linkage in familiesPp .0079
with IBD (Cho et al. 1998). Marker D12S1052 (Pp
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) at 12q21.2 has been linked to multiple sclerosis.0227
(MS [MIM 126200]) (Haines et al. 1996). Another
chromosomal region that raises interest is 16q24.1.
Markers in that region have been implicated in IBD
(Cho et al. 1998) and ankylosing spondylitis (AS [MIM
106300]; Brown et al. 1998), as well as in RA as de-
scribed above (Corne´lis et al. 1998).
As noted already, there are a number of regions of
potential overlap between this study and other RA link-
age studies (Corne´lis et al. 1998; Barton et al. 2000).
There are also discrepancies. Some of these may be due
to type I error or may stem from differences in the ethnic
compositions of the various family collections. It is
likely that underlying genetic heterogeneity may explain
differences among the studies. Epistatic interactions
clearly influence expression of disease in murine models
of autoimmunity (Morel et al. 2000). If RA in humans
reflects epistatic interactions, then large data sets will
be required to delineate all genetic factors; smaller stud-
ies may find some, but not all, of the causative genetic
factors. Stratification of RA family data sets on the basis
of genetic, as well as clinical, characteristics may help
reveal these interactions. In this regard, we have done
a preliminary stratification of our families by HLA-
DR4. This has not shown significant differences from
the full genome screen. Collaborative studies among the
groups performing RA genome screens will allow fur-
ther evaluation of our positive linkage findings on chro-
mosomes 1, 4, 12, 16, and 17.
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